{"name":"Zhang Xiaofeng,MD","slug":"zhang-xiaofeng-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Tegoprazan 50 mg, tablets, orally, bid","genericName":"Tegoprazan 50 mg, tablets, orally, bid","slug":"tegoprazan-50-mg-tablets-orally-bid","indication":"Other","status":"marketed"},{"name":"Tegoprazan 50 mg, tablets, orally, qd","genericName":"Tegoprazan 50 mg, tablets, orally, qd","slug":"tegoprazan-50-mg-tablets-orally-qd","indication":"Gastroesophageal reflux disease (GERD)","status":"marketed"}]}],"pipeline":[{"name":"Tegoprazan 50 mg, tablets, orally, bid","genericName":"Tegoprazan 50 mg, tablets, orally, bid","slug":"tegoprazan-50-mg-tablets-orally-bid","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tegoprazan 50 mg, tablets, orally, qd","genericName":"Tegoprazan 50 mg, tablets, orally, qd","slug":"tegoprazan-50-mg-tablets-orally-qd","phase":"marketed","mechanism":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Acid-related gastrointestinal disorders"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}